目的 探討帕羅西汀聯(lián)合坦度螺酮治療高血壓致焦慮的臨床療效。方法 選取2016年1月-2017年1月在中國人民武裝警察部隊山東省總隊醫(yī)院進行治療的104例高血壓致焦慮患者，根據(jù)治療方案分為對照組和治療組，每組各52例。對照組口服枸櫞酸坦度螺酮片，10 mg/次，3次/d。治療組在對照組基礎(chǔ)上口服鹽酸帕羅西汀片，初始劑量20 mg/d，每周以10 mg遞增，最大劑量不超過40 mg/d。兩組患者均治療4周。觀察兩組患者的臨床療效，同時比較兩組治療前后漢密爾頓焦慮量表（HAMA）評分、PHQ-9評分、WHOQOL-BREF評分、5-羥色胺（5-HT）、去甲腎上腺素（NA）及神經(jīng)肽Y（NPY）水平的變化情況。結(jié)果 治療后，對照組和治療組的總有效率分別為80.77%、98.08%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組HAMA評分、PHQ-9評分、NPY、5-HT、NA均顯著降低，而WHOQOL-BREF評分均顯著增加，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；治療后，治療組HAMA評分、PHQ-9評分、NPY、5-HT、NA低于對照組，WHOQOL-BREF評分高于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 帕羅西汀聯(lián)合坦度螺酮治療高血壓致焦慮具有較好的臨床療效，可有效改善的焦慮癥狀，降低血清NPY、5-HT、NE水平，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of paroxetine combined with tandospirone in treatment of anxiety induced by hypertension. Methods Patients (104 cases) with anxiety induced by hypertension in General Team Hospital in Shandong Province of the Chinese People's Armed Police Force from January 2016 to January 2017 were divided into control and treatment groups according to the treatment, and each group had 52 cases. Patients in the control group were po administered with Tandospirone Citrate Tablets, 10 mg/time, three times daily. Patients in the treatment group were po administered with Paroxetine Hydrochloride Tablets on the basis of the control group, the initial dosage was 20 mg/d, and the maximum dosage did not exceed 40 mg/d by increasing 10 mg per week. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the changes of HAMA score, PHQ-9 score, WHOQOL-BREF score, 5-HT, NA, and NPY in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.77% and 98.08%, respectively, and there was difference between two groups (P < 0.05). After treatment, HAMA score, PHQ-9 score, NPY, 5-HT, and NA in two groups were significantly decreased, but WHOQOL-BREF score was significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, HAMA score, PHQ-9 score, NPY, 5-HT, and NA in the treatment group were lower than those in the control group, WHOQOL-BREF score was higher than that in the control group, and there were differences between two groups (P < 0.05). Conclusion Paroxetine combined with tandospirone has significant clinical efficacy in treatment of anxiety induced by hypertension, and can improve the anxiety symptoms effectively and reduce the levels of NPY, 5-HT, and NE, which has a certain clinical application value.